ADVM — Adverum Biotechnologies Share Price
0.000.00%
Last trade - 00:00- $190.74m
- $94.21m
- $3.60m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.29 | ||
| Price to Tang. Book | 2.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 52.98 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -83.72% | ||
| Return on Equity | -88.43% | ||
| Operating Margin | -3444.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.25 | n/a | 7.5 | n/a | 3.6 | n/a | n/a | 17.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Directors
- Patrick Machado NEC (57)
- Laurent Fischer PRE (57)
- Rupert D Souza CFO (62)
- Peter Soparkar COO (50)
- Brigit Riley CSO
- Jon Williams VPR
- Richard Beckman OTH
- Star Seyedkazemi OTH
- Mark Lupher IND (50)
- James Scopa IND (62)
- Dawn Svoronos IND (67)
- Reed Tuckson IND (70)
- Scott Whitcup IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 17th, 2006
- Public Since
- July 31st, 2014
- No. of Shareholders
- 37
- No. of Employees
- 121
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 20,754,915
- Address
- 100 Cardinal Way, REDWOOD CITY, 94063
- Web
- https://adverum.com/
- Phone
- +1 6506491004
- Auditors
- Ernst & Young LLP
Upcoming Events for ADVM
Adverum Biotechnologies Inc Annual Shareholders Meeting
Q2 2024 Adverum Biotechnologies Inc Earnings Release
Similar to ADVM
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Adverum Biotechnologies share price?
As of Today at 19:00 UTC, shares in Adverum Biotechnologies are trading at $9.19. This share price information is delayed by 15 minutes.
How has the Adverum Biotechnologies share price performed this year?
Shares in Adverum Biotechnologies last closed at $9.19 and the price had moved by +12.39% over the past 365 days. In terms of relative price strength the Adverum Biotechnologies share price has underperformed the S&P500 Index by -8.12% over the past year.
What are the analyst and broker recommendations for Adverum Biotechnologies?
The overall consensus recommendation for Adverum Biotechnologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Adverum Biotechnologies dividend yield?
Adverum Biotechnologies does not currently pay a dividend.
Does Adverum Biotechnologies pay a dividend?
Adverum Biotechnologies does not currently pay a dividend.
When does Adverum Biotechnologies next pay dividends?
Adverum Biotechnologies does not currently pay a dividend.
How do I buy Adverum Biotechnologies shares?
To buy shares in Adverum Biotechnologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adverum Biotechnologies?
As of the previous close price of $9.19, shares in Adverum Biotechnologies had a market capitalisation of $190.74m.
Where are Adverum Biotechnologies shares listed?
Here are the trading details for Adverum Biotechnologies:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ADVM
What kind of share is Adverum Biotechnologies?
Based on an overall assessment of its quality, value and momentum Adverum Biotechnologies is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adverum Biotechnologies share price forecast for 2024?
The analyst consensus target price for shares in Adverum Biotechnologies is $40.00. That is 335.26% above the last closing price of $9.19.
Analysts covering Adverum Biotechnologies currently have a consensus Earnings Per Share (EPS) forecast of -$5.41 for the next financial year.
What is the trend in the Adverum Biotechnologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adverum Biotechnologies. Over the past six months, its share price has underperformed the S&P500 Index by -20.95%.
As of the last closing price of $9.19, shares in Adverum Biotechnologies were trading -33.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adverum Biotechnologies PE Ratio?
The Adverum Biotechnologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Adverum Biotechnologies?
Adverum Biotechnologies' management team is headed by:
- Patrick Machado - NEC
- Laurent Fischer - PRE
- Rupert D Souza - CFO
- Peter Soparkar - COO
- Brigit Riley - CSO
- Jon Williams - VPR
- Richard Beckman - OTH
- Star Seyedkazemi - OTH
- Mark Lupher - IND
- James Scopa - IND
- Dawn Svoronos - IND
- Reed Tuckson - IND
- Scott Whitcup - IND